VTAK Overview

Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.

Wall Street analysts forecast VTAK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTAK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Catheter Precision Inc revenue for the last quarter amounts to 226.00K USD, increased 135.42

Catheter Precision Inc. EPS for the last quarter amounts to -1.70 USD, decreased -95.55

Catheter Precision Inc (VTAK) has 22 emplpoyees as of March 11 2026.

Today VTAK has the market capitalization of 2.99M USD.